| Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma DA Braun, Y Hou, Z Bakouny, M Ficial, M Sant’Angelo, J Forman, ... Nature medicine 26 (6), 909-918, 2020 | 606 | 2020 |
| Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma NM Tannir, S Signoretti, TK Choueiri, DF McDermott, RJ Motzer, A Flaifel, ... Clinical Cancer Research 27 (1), 78-86, 2021 | 195 | 2021 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 104 | 2021 |
| PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials … A Flaifel, W Xie, DA Braun, M Ficial, Z Bakouny, AH Nassar, RB Jennings, ... Clinical Cancer Research 25 (20), 6080-6088, 2019 | 56 | 2019 |
| Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma M Ficial, OA Jegede, M Sant'Angelo, Y Hou, A Flaifel, JC Pignon, ... Clinical Cancer Research 27 (5), 1371-1380, 2021 | 53 | 2021 |
| A subset of localized prostate cancer displays an immunogenic phenotype associated with losses of key tumor suppressor genes C Calagua, M Ficial, CS Jansen, T Hirz, L Del Balzo, S Wilkinson, R Lake, ... Clinical Cancer Research 27 (17), 4836-4847, 2021 | 26 | 2021 |
| Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation P Tomei, V Masola, S Granata, G Bellin, P Carratù, M Ficial, VA Ventura, ... Journal of nephrology 29, 881-891, 2016 | 25 | 2016 |
| Keratin-14 expression in pneumocytes as a marker of lung regeneration/repair during diffuse alveolar damage M Ficial, C Antonaglia, M Chilosi, M Santagiuliana, AO Tahseen, ... American journal of respiratory and critical care medicine 189 (9), 1142-1145, 2014 | 18 | 2014 |
| Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR … C Fiorini, F Massari, S Pedron, S Sanavio, C Ciccarese, AB Porcaro, ... American Journal of Cancer Research 4 (6), 907, 2014 | 16 | 2014 |
| Liver metastases from renal oncocytoma with vascular extension G Cacciamani, L Cima, M Ficial, G Novella, S Siracusano, U Tedeschi, ... Applied Immunohistochemistry & Molecular Morphology 27 (5), e48-e53, 2019 | 13 | 2019 |
| Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. M Ficial, O Jegede, M Sant'Angelo, S Moreno, DA Braun, M Wind-Rotolo, ... Journal of Clinical Oncology 38 (15_suppl), 5023-5023, 2020 | 9 | 2020 |
| Keratin14 mRNA expression in human pneumocytes during quiescence, repair and disease M Confalonieri, E Buratti, G Grassi, R Bussani, M Chilosi, R Farra, ... PLoS One 12 (2), e0172130, 2017 | 9 | 2017 |
| Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma RM Saliby, T El Zarif, Z Bakouny, V Shah, W Xie, R Flippot, T Denize, ... Cancer Immunology Research 11 (8), 1114-1124, 2023 | 8 | 2023 |
| Develop dual-targeted CAR-T cells to achieve RCC cures Y Wang, M Grimaud, A Buck, A Fayed, M Chang, R Jennings, ... Cancer Research 80 (16_Supplement), 6606-6606, 2020 | 6 | 2020 |
| Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... bioRxiv, 2020.05. 28.121806, 2020 | 4 | 2020 |
| development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC) Y Wang, A Buck, M Grimaud, S Kodangattil, C Razimbaud, A Fayed, ... Cancer Research 81 (13_Supplement), 62-62, 2021 | 2 | 2021 |
| Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. DA Braun, Y Hou, Z Bakouny, M Ficial, M Sant'Angelo, P Ross-Macdonald, ... Journal of Clinical Oncology 38 (15_suppl), 5010-5010, 2020 | 2 | 2020 |
| Update on acute repiratory distress syndrome’s pathology. recent insights into in vivo alveolar regeneration M Ficial, M Chilosi Shortness of Breath 3, 102-7, 2014 | 2 | 2014 |
| Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects Y Wang, A Buck, B Piel, L Zerefa, N Murugan, CD Coherd, AG Miklosi, ... Molecular Cancer 23 (1), 56, 2024 | 1 | 2024 |
| 295 Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects Y Wang, A Buck, M Lynch, G Kastrunes, JW Cho, M Grimaud, D Braun, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
